Skip to content

Production & Supply

Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.

ThumbnailKalusPhotoPlasma & Platelets

How can we guarantee the supply of blood products to patients? Especially with short-life platelet concentrates, even in times of epidemics?

Priv-Doz. Dr. med. Ulrich Kalus
Charité
Berlin, Germany 

EN DE

Screenshot 2022-07-15 at 11.57.51

Platelets

Pathogen reduction of double dose platelet concentrates from pools of eight Buffy coats: product quality, safety and economic aspects 

Dr. Konrad Rosskopf
Dept. Transfusion Medicine
University Hospital of Graz, Austria

EN DE ES PL RU

ThumbnailAbediPlatelets

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products Using the INTERCEPT Blood System

Dr. Mohammad R. Abedi, MD, PhD
Örebro University Hospital
Stockholm, Sweden

EN 

ThumbnailPayratPlatelets

How pools-of-pools contributes to optimising your PI platelet products

Mr. Jean-Marc Payrat
Cerus Europe B.V.
Amersfoort, the Netherlands

EN

ThumbnailGoslings

Plasma

Production and in vitro quality of pooled whole blood derived PI plasma

Dr. sc. nat. David Goslings, MBA
Blood Transfusion Service Zurich
Zurich, Switzerland

EN DE   

ThumbnailRamirezPlatelets

Timing of bacterial inactivation/ testing

Dr. Sandra Ramirez-Arcos, PhD
Canadian Blood Services
Ottawa, Canada

EN

ThumbnailRosskopfPlasma & Cryoprecipitate

Cryoprecipitate from pathogen reduced concurrent apheresis plasma: 5-day post-thaw room temperature storage after 2-year frozen shelf-life

Dr. Konrad Rosskopf, MD
Medical University Graz
Graz, Austria

EN

ThumbnailTennby

Platelets 

Case study: enabling double dose methodology on Reveos through pathogen inactivation

 

Ms. Eleonore Tennby
Cerus Europe B.V.

Amersfoort, the Netherlands

EN   

ThumbnailLandroPlatelets & Plasma

Case study: impact of pathogen inactivation on outdating rates and supply continuity

Ms. Ragna Landrö, BSc
The Blood Bank, The National University Hospital of Iceland, Reykjavík
Reykjavík, Iceland

EN

ThumbnailAbedi-1Platelets

Overview of the variability in platelet production processes and applied safety measures

Dr. Mohammad R. Abedi, PhD
Örebro University Hospital
Örebro, Sweden

EN

ThumbnailAuvinen

Plasma 

Experiences of standardized volume, pathogen-reduced, pooled plasma for faster availability of components for transfusion

Ms. Marja-Kaisa Auvinen, MD, PhD
Uppsala University Hospital
Uppsala, Sweden

 

EN  

ThumbnailStanfordPlatelets 

Stanford Blood Center - the first blood center of its size to implement pathogen reduction for 100% of platelet components

Stanford Blood Center
California, United States

EN

ThumbnailBareaPhotoPlatelets & Plasma

COVID-19: Lessons learned to safeguard the continuity of blood supply in the Madrid region

Dr. Luisa Maria Barea Garcia, MD
Centro de Transfusión de la Comunidad de Madrid
Madrid, Spain

EN DE ES IT

  

  

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 000157, v43.0